المؤلفون: Xiang-Ting Chen, Qian Zhang, Fei-Fei Chen, Si-Yuan Wen, Chang-Qing Zhou

المصدر: Frontiers in Neurology, Vol 14 (2023)

مصطلحات موضوعية: Parkinson's disease, network meta-analysis, dopamine-receptor agonists, ropinirole, piribedil, rotigotine, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://www.frontiersin.org/articles/10.3389/fneur.2023.1183823/fullTest; https://doaj.org/toc/1664-2295Test

الوصول الحر: https://doaj.org/article/0cdf6e3cb134458eb3266f2c8dd0d5efTest

المؤلفون: E. V. Yakovenko, F. A. Abbasov

المصدر: Неврология, нейропсихиатрия, психосоматика, Vol 14, Iss 4, Pp 103-107 (2022)

مصطلحات موضوعية: parkinson's disease, non-motor symptoms, apathy, depression, dementia, piribedil, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://nnp.ima-press.net/nnp/article/view/1869Test; https://doaj.org/toc/2074-2711Test; https://doaj.org/toc/2310-1342Test

الوصول الحر: https://doaj.org/article/cd00f5dc01f8453bb97b0f39cd56b4f1Test

المؤلفون: E. A. Katunina, Z. A. Zalyalova, D. V. Pokhabov, M. Z. Ivanova, A. M. Semenova, Е. А. Катунина, З. А. Залялова, Д. В. Похабов, М. З. Иванова, А. М. Семенова

المساهمون: This article has been supported by Servier, Статья спонсируется компанией «Сервье»

المصدر: Neurology, Neuropsychiatry, Psychosomatics; Vol 15, No 3 (2023); 95-103 ; Неврология, нейропсихиатрия, психосоматика; Vol 15, No 3 (2023); 95-103 ; 2310-1342 ; 2074-2711 ; 10.14412/2074-2711-2023-3

مصطلحات موضوعية: пирибедил, initial stages, dopamine receptor agonists, piribedil, начальные стадии, агонисты дофаминовых рецепторов

وصف الملف: application/pdf

العلاقة: https://nnp.ima-press.net/nnp/article/view/2036/1542Test; Tysnes O-B, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm (Vienna). 2017 Aug;124(8):901-5. doi:10.1007/s00702-017-1686-y. Epub 2017 Feb 1.; Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003 MarApr;24(2):197-211. doi:10.1016/s01974580(02)00065-9; Pinter B, Diem-Zangerl A, Wenning GK, et al. Mortality in Parkinson’s disease: a 38-year follow-up study. Mov Disord. 2015 Feb;30(2):266-9. doi:10.1002/mds.26060. Epub 2014 Dec 1. Erratum in: Mov Disord. 2017 Jan;32(1):178.; Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. doi:10.1212/01.wnl.0000247740.47667.03. Epub 2006 Nov 2.; Lunati A, Lesage S, Brice A. The genetic landscape of Parkinson’s disease. Rev Neurol (Paris). 2018 Nov;174(9):628-43. doi:10.1016/j.neurol.2018.08.004. Epub 2018 Sep 21.; Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007 Dec;33(6):599-614. doi:10.1111/j.13652990.2007.00874.x. Epub 2007 Oct 24.; Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm (Vienna). 2003 May;110(5):517-36. doi:10.1007/s00702-002-0808-2; Borghammer P. How does Parkinson’s disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov Disord. 2018 Jan;33(1):4857. doi:10.1002/mds.27138. Epub 2017 Aug 26.; Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol. 2014 Dec;128(6):80520. doi:10.1007/s00401-014-1343-6. Epub 2014 Oct 9.; Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann Neurol. 2016 Jun;79(6):940-9. doi:10.1002/ana.24648. Epub 2016 Apr 9.; Pan-Montojo F, Anichtchik O, Dening Y, et al. Progression of Parkinson’s disease pathology is reproduced by intragastric administration of rotenone in mice. PLoS One. 2010 Jan 19;5(1):e8762. doi:10.1371/journal.pone.0008762; Svensson E, Horvath-Puho E, Thomsen RW, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015 Oct;78(4):522-9. doi:10.1002/ana.24448. Epub 2015 Jul 17.; Liu B, Fang F, Pedersen NL, et al. Vagotomy and Parkinson disease: A Swedish register-based matched-cohort study. Neurology. 2017 May 23;88(21):1996-2002. doi:10.1212/WNL.0000000000003961. Epub 2017 Apr 26.; Lionnet A, Leclair-Visonneau L, Neunlist M, et al. Does Parkinson’s disease start in the gut? Acta Neuropathol. 2018 Jan;135(1):1-12. doi:10.1007/s00401-0171777-8. Epub 2017 Oct 16.; Gjerloff T, Fedorova T, Knudsen K, et al. Imaging acetylcholinesterase density in peripheral organs in Parkinson’s disease with 11C-donepezil PET. Brain. 2015 Mar;138(Pt 3):653-63. doi:10.1093/brain/awu369. Epub 2014 Dec 23.; Knudsen K, Fedorova TD, Hansen AK, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018 Jul;17(7):618-28. doi:10.1016/S14744422(18)30162-5. Epub 2018 Jun 1.; Iranzo A, Fernandez-Arcos A, Tolosa E, et al. Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS One. 2014 Feb 26;9(2):e89741. doi:10.1371/journal.pone.0089741; Miyamoto T, Miyamoto M, Inoue Y, et al. Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology. 2006 Dec 26;67(12):2236-8. doi:10.1212/01.wnl.0000249313.25627.2e; Kashihara K, Imamura T, Shinya T. Cardiac 123I-MIBG uptake is reduced more markedly in patients with REM sleep behavior disorder than in those with early stage Parkinson’s disease. Parkinsonism Relat Disord. 2010 May;16(4):252-5. doi:10.1016/j.parkreldis.2009.12.010. Epub 2010 Jan 25.; Orimo S, Yogo M, Nakamura T, et al. (123)I-meta-iodobenzylguanidine (MIBG) cardiac scintigraphy in α-synucleinopathies. Ageing Res Rev. 2016 Sep;30:122-33. doi:10.1016/j.arr.2016.01.001. Epub 2016 Feb 2.; Knudsen K, Fedorova TD, Horsager J, et al. Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinson’s Disease Subtypes. J Parkinsons Dis. 2021;11(4):1677-87. doi:10.3233/JPD-212761; Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain. 2020 Oct 1;143(10):3077-88. doi:10.1093/brain/awaa238; Borghammer P. The α-synuclein origin and Connectome Model (SOC model) of Parkinson’s disease: Explaining motor asymmetry, non-motor phenotypes, and cognitive decline. J Parkinson’s Dis. 2021;11(2):455-74. doi:10.3233/JPD-202481; Berg D, Postuma RB, Adler CH, et al. MDS research criteria for Prodromal Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1600-11. doi:10.1002/mds.26431; Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015 Oct;30(12):1591-601. doi:10.1002/mds.26424; Иллариошкин СН, Левин ОС, редакторы. Руководство по диагностике и лечению болезни Паркинсона. Москва: ООО «ИПК Парето-Принт»; 2017. 336 с.; Селихова МВ, Катунина ЕА, Воун А. Позитронная эмиссионная и однофотонная эмиссионная компьютерная томография в оценке состояния моноаминергических систем мозга при экстрапирамидных расстройствах. Анналы клинической и экспериментальной неврологии. 2019;13(2):69-78. doi:10.25692/ACEN.2019.2.8; Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма. Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/716_1Test Bolezn’ Parkinsona, vtorichnyi parkinsonism i drugie zabolevaniya, proyavlyayushchiesya sindromom parkinsonizma; Нарушения обмена меди (болезнь Вильсона). Клинические рекомендации. 2021. Доступно по ссылке: https://cr.minzdrav.gov.ru/recomend/376_2Test; Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-es recommendations for the diagnosis of Parkinson’s disease. Eur J Neurol. 2013 Jan;20(1):16-34. doi:10.1111/ene.12022. Erratum in: Eur J Neurol. 2013 Feb;20(2):406.; D Med Collaborative Group; Gray R, Ives N, Rick C, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet. 2014 Sep 27;384(9949):1196-205. doi:10.1016/S0140-6736(14)60683-8. Epub 2014 Jun 11. Erratum in: Lancet. 2014 Sep 27;384(9949):1186.; Bergamasco B, Frattola L, Muratorio A, et al. Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand. 2000 Jun;101(6):372-80. doi:10.1034/j.16000404.2000.90295a.x; Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology. 1997 Sep;49(3):724-8. doi:10.1212/wnl.49.3.724. Erratum in: Neurology. 1998 Mar;50(3):838.; Finotti N, Castagna L, Moretti A, Marzatico F. Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment. Pharmacol Res. 2000;42(4):287-91. doi:10.1006/phrs.2000.0690; Le W-D, Jankovic J. Are dopamine receptors agonists neuroprootective in Parkinson’s disease? Drugs Aging. 2001;18(6):389-96. doi:10.2165/00002512-200118060-00001; Nishibayashi S, Asanuma M, Kohno M, et al. Scavenging effects of dopamine agonists on nitric oxide radicals. J Neurochem. 1996;67(5):2208-11. doi:10.1046/j.14714159.1996.67052208.x; Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. New Engl J Med. 2000;342(20):1484-91. doi:10.1056/nejm200005183422004; Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002 Apr 3;287(13):1653-61. doi:10.1001/jama.287.13.1653; Whone AL, Watts RL, Stoessl AJ, et al; REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003 Jul;54(1):93-101. doi:10.1002/ana.10609; Schapira A, Albrecht S, Barone P, et al. P1.203 immediate vs. delayed-start pramipexole in early Parkinson’s disease: The proud study. Parkinsonism Relat Disord. 2009;15:S81. doi:10.1016/s1353-8020(09)70325-6; Gerlach M, Double K, Arzberger T, et al. Dopamine receptor agonists in current clinical use: Comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transmis. 2003;110(10):1119-27. doi:10.1007/s00702-003-0027-5; Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease. Drug Saf. 2001;24(11):863-8. doi:10.2165/00002018200124110-00007; Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease. Drug Saf. 2009;32(6):475-88. doi:10.2165/00002018-200932060-00004; Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson’s disease. Arch Neurol. 2010 May;67(5):589-95. doi:10.1001/archneurol.2010.65; Isaias IU, Siri C, Cilia R, et al. The relationship between impulsivity and impulse control disorders in Parkinson’s disease. Mov Disord. 2008;23(3):411-5. doi:10.1002/mds.21872; Weintraub D, Hoops S, Shea JA, et al. Validation of the questionnaire for impulsivecompulsive disorders in Parkinson’s disease. Mov Disord. 2009;24(10):1461-7. doi:10.1002/mds.22571; Weintraub D, Rektorova I. Impulse control disorders and related behaviors. In: D Aarsland, J Cummings, D Weintraub, K Chaudhuri, editors. Neuropsychiatric and Cognitive Changes in Parkinson’s Disease and Related Movement Disorders: Diagnosis and Management. Cambridge: Cambridge University Press; 2013. P. 140-52. doi:10.1017/CBO9781139856669.014; Joutsa J, Martikainen K, Vahlberg T, et al. Impulse control disorders and depression in Finnish patients with Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(2):155-60. doi:10.1016/j.parkreldis.2011.09.007; Antonini A, Barone P, Bonuccelli U, et al. Icarus study: Prevalence and clinical features of impulse control disorders in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2017;88(4):317-24. doi:10.1136/jnnp-2016315277; Thorlund K, Wu P, Druyts E, et al. Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis. Neuropsychiatr Dis Treatm. 2014;2014:767-76. doi:10.2147/ndt.s60061; LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson’s disease. Clin Neuropharmacol. 2007;30(5):256-65. doi:10.1097/wnf.0b013e318154c7c4; Millan MJ. From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson’s disease. Pharmacol Ther. 2010;128(2):229-73. doi:10.1016/j.pharmthera.2010.06.002; Gobert A, Di Cara B, Cistarelli L, Millan MJ. Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of α2aadrenoceptors: A dialysis comparison to Talipexole and Quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exper Ther. 2003;305(1):338-46. doi:10.1124/jpet.102.046383; Delaville C, Deurwaerdere PD, Benazzouz A. Noradrenaline and Parkinson’s disease. Front Syst Neurosci. 2011 May 18;5:31. doi:10.3389/fnsys.2011.00031. eCollection 2011.; Djaldetti R, Mosberg-Galili R, Sroka H, et al. Camptocormia (Bent Spine) in patients with Parkinson’s disease characterization and possible pathogenesis of an unusual phenomenon. Mov Disord. 1999;14(3):443-7. doi:10.1002/1531-8257(199905)14:33.0.co;2-g; Suzuki M, Hirai T, Ito Y, et al. Pramipexole-induced antecollis in Parkinson’s disease. J Neurol Sci. 2008;264(1-2):195-7. doi:10.1016/j.jns.2007.08.008; Calzi F, Bellasio R, Guiso G, et al. Effect of piribedil and its metabolite, S584, on brain lipid peroxidation in vitro and in vivo. Eur J Pharmacol. 1997;338(2):185-90. doi:10.1016/s0014-2999(97)81947-4; Munchau A. Pharmacological treatment of Parkinson’s disease. Postgrad Med J. 2000;76(900):602-10. doi:10.1136/pmj.76.900.602; Rascol O, Dubois B, Caldas AC, et al. Early Piribedil monotherapy of Parkinson’s disease: A planned seven-month report of the Regain Study. Mov Disord. 2006;21(12):2110-5. doi:10.1002/mds.21122; Rondot P, Ziegler M. Activity and acceptability of Piribedil in Parkinson’s disease: A multicentre study. J Neurol. 1992;239 Suppl 1:S28-34. doi:10.1007/BF00819564; Chen X, Ren C, Li J, et al. The efficacy and safety of Piribedil relative to pramipexole for the treatment of early Parkinson’s disease: A systematic literature review and network meta-analysis. Clin Neuropharmacol. 2020;43(4):100-6. doi:10.1097/wnf.0000000000000400; Aarsland D, Bronnick K, Larsen JP, et al. Cognitive impairment in incident, untreated Parkinson’s disease: The Norwegian Parkwest Study. Neurology. 2009;72(13):1121-6. doi:10.1212/01.wnl.0000338632.00552.cb; Aarsland D, Bronnick K, Williams-Gray C, et al. Mild cognitive impairment in Parkinson’s disease: A Multicenter pooled analysis. Neurology. 2010;75(12):1062-9. doi:10.1212/wnl.0b013e3181f39d0e; Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: Critical review of pd-MCI. Mov Disord. 2011;26(10):1814-24. doi:10.1002/mds.23823; Yarnall AJ, Breen DP, Duncan GW, et al. Characterizing mild cognitive impairment in incident Parkinson’s disease: The Icicle-PD Study. Neurology. 2014;82(4):308-16. doi:10.1212/wnl.0000000000000066; Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson’s disease. J Neurol Sci. 2010;289(1-2):18-22. doi:10.1016/j.jns.2009.08.034; Buter TC, van den Hout A, Matthews FE, et al. Dementia and survival in Parkinson’s disease: A 12-year population study. Neurology. 2008;70(13):1017-22. doi:10.1212/01.wnl.0000306632.43729.24; Svenningsson P, Westman E, Ballard C, Aarsland D. Cognitive impairment in patients with Parkinson’s disease: Diagnosis, biomarkers, and treatment. Lancet Neurol. 2012;11(8):697707. doi:10.1016/s1474-4422(12)70152-7; Федорова НВ, Артемьева ЕГ, Чигирь ИП, Левин ОС. Применение пронорана (пирибедила) при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2003;103(9):71-2.; Пилипович АА, Голубев ВЛ. Влияние Пронорана на когнитивные и аффективные нарушения при болезни Паркинсона. Журнал неврологии и психиатрии им. С.С. Корсакова. 2005;105(4):41-7.; Ollat H. Dopaminergic insufficiency reflecting cerebral ageing: Value of a dopaminergic agonist, Piribedil. J Neurol. 1992;239(S1):13-6. doi:10.1007/bf00819561; Valdes P, Schneider BL. Gene therapy: A promising approach for neuroprotection in Parkinson’s disease? Front Neuroanat. 2016 Dec 20;10:123. doi:10.3389/fnana.2016.00123.eCollection2016.; Brocco M, Dekeyne A, Papp M, Millan MJ. Antidepressant-like properties of the anti-parkinson agent, Piribedil, in rodents: Mediation by dopamine D2 receptors. Behav Pharmacol. 2006;17(7):559-72. doi:10.1097/01.fbp.0000236267.41806.5b; Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex – basal ganglia circuits. Cerebral Cortex. 2006;16(7):916-28. doi:10.1093/cercor/bhj043; Dujardin K, Defebvre L. Apathy in Parkinson’s disease: What are the underlying mechanisms? Neurology. 2012;79(11):1082-3. doi:10.1212/wnl.0b013e3182698dd4; Starkstein SE. Apathy in Parkinson’s disease: Diagnostic and Etiological Dilemmas. Mov Disord. 2012;27(2):174-8. doi:10.1002/mds.24061; Pluck GC. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002 Dec;73(6):636-42. doi:10.1136/jnnp.73.6.636; Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson’s disease. Mov Disord. 2009;24(15):2175-86. doi:10.1002/mds.22589; Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010;9(6):573-80. doi:10.1016/s1474-4422(10)70106-x; Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in Advanced Parkinson’s Disease. N Engl J Med. 2003;349(20):1925-34. doi:10.1056/nejmoa035275; Funkiewiez A. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834-9. doi:10.1136/jnnp.2002.009803; Czernecki V, Schüpbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson’s disease: A dopamine responsive symptom. Mov Disord. 2008;23(7):964-9. doi:10.1002/mds.21949; Witt K, Daniels C, Reiff J, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson’s disease: A randomised, Multicentre Study. Lancet Neurol. 2008;7(7):605-14. doi:10.1016/s1474-4422(08)70114-5; Remy P, Doder M, Lees A, et al. Depression in Parkinson’s disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain. 2005;128(6):131422. doi:10.1093/brain/awh445; Thobois S, Ardouin C, Lhommee E, et al. Non-motor dopamine withdrawal syndrome after surgery for Parkinson’s disease: Predictors and underlying mesolimbic denervation. Brain. 2010;133(4):1111-27. doi:10.1093/brain/awq032; Schrag A. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69(3):30812. doi:10.1136/jnnp.69.3.308; Voon V, Fernagut P-O, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson’s disease: From Dyskinesias to impulse control disorders. Lancet Neurol. 2009;8(12):1140-9. doi:10.1016/s14744422(09)70287-x; Chaudhuri KR, Schapira AHV. Non-motor symptoms of Parkinson’s disease: Dopaminergic pathophysiology and treatment. Lancet Neurol. 2009;8(5):464-74. doi:10.1016/s1474-4422(09)70068-7; Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with Piribedil. Brain. 2013;136(5):1568-77. doi:10.1093/brain/awt067; Paus S, Brecht HM, Köster J, et al. Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson’s disease. Mov Disord. 2003;18(6):659-67. doi:10.1002/mds.10417; Borek LL, Amick MM, Friedman JH. Non-motor aspects of Parkinson’s disease. CNSSpectrums. 2006;11(7):541-54. doi:10.1017/s1092852900013560; Tracik F, Ebersbach G. Sudden daytime sleep onset in Parkinson’s disease: Polysomnographic recordings. Mov Disord. 2001;16(3):500-6. doi:10.1002/mds.1083; Ulivelli M, Rossi S, Lombardi C, et al. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD. Neurology. 2002;58(3):462-5. doi:10.1212/wnl.58.3.462; Allcock LM, Rowan EN, Steen IN, et al. Impaired attention predicts falling in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(2):110-5. doi:10.1016/j.parkreldis.2008.03.010; Meindorfner C, Körner Y, Möller JC, et al. Driving in Parkinson’s disease: Mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord. 2005;20(7):832-42. doi:10.1002/mds.20412; Drouot X, Moutereau S, Nguyen JP, et al. Low levels of ventricular CSF orexin/hypocretin in Advanced PD. Neurology. 2003;61(4):540-3. doi:10.1212/01.wnl.0000078194.53210.48; Poewe W, Hogl B. Sleep and Parkinson’s disease. Editional review. Curr Opin Neurol. 2000 Aug;13(4):423-6. doi:10.1097/00019052200008000-00009; Verbaan D, van Rooden SM, Visser M, et al. Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord. 2008;23(1):35-41. doi:10.1002/mds.21727; Wood LD. Clinical Review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging. 2010;27(4):295-310. doi:10.2165/11318330000000000-00000; Monaca C, Duhamel A, Jacquesson JM, et al. Vigilance troubles in Parkinson’s disease: A subjective and objective polysomnographic study. Sleep Med. 2006;7(5):448-53. doi:10.1016/j.sleep.2005.12.002; Frucht S, Rogers JD, Greene PE, et al. Falling asleep at the wheel: Motor Vehicle Mishaps in persons taking pramipexole and Ropinirole. Neurology. 1999 Jun 10;52(9):1908-10. doi:10.1212/wnl.52.9.1908; Eggert K, Еhlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist Piribedil on vigilance in patients with Parkinson’s disease and excessive daytime sleepiness (PiViCog-PD). Clin Neuropharmacol. 2014;37(4):116-22. doi:10.1097/wnf.0000000000000041; Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of Antiparkinson agents at multiple classes of monoaminergic receptor. i. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exper Ther. 2002;303(2):791-804. doi:10.1124/jpet.102.039867; Katunina EA, Blokhin V, Nodel MR, et al. Searching for biomarkers in the blood of patients at risk of developing Parkinson’s disease at the Prodromal Stage. Int J Mol Sci. 2023;24(3):1842. doi:10.3390/ijms24031842; https://nnp.ima-press.net/nnp/article/view/2036Test

الإتاحة: https://doi.org/10.14412/2074-2711-2023-3-95-103Test
https://doi.org/10.14412/2074-2711-2023-3Test
https://doi.org/10.1007/s00702-017-1686-yTest
https://doi.org/10.1016/s01974580Test(02)00065-9
https://doi.org/10.1002/mds.26060Test
https://doi.org/10.1212/01.wnl.0000247740.47667.03Test
https://doi.org/10.1016/j.neurol.2018.08.004Test
https://doi.org/10.1111/j.13652990.2007.00874.xTest
https://doi.org/10.1007/s00702-002-0808-2Test
https://doi.org/10.1007/s00401-014-1343-6Test

المؤلفون: Murat Mert Atmaca, Başar Bilgiç, Haşmet Hanağası

المصدر: Türk Nöroloji Dergisi, Vol 27, Iss 2, Pp 192-194 (2021)

مصطلحات موضوعية: parkinsonism, pisa syndrome, piribedil, dopamine agonists, Medicine, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://tjn.org.tr/jvi.aspx?pdir=tjn&plng=eng&un=TJN-28000&look4Test=; https://doaj.org/toc/1309-2545Test

الوصول الحر: https://doaj.org/article/3ad7a7828a1b4742a6336a10a5456228Test

المؤلفون: A. Yu. Emelin

المصدر: Неврология, нейропсихиатрия, психосоматика, Vol 12, Iss 5, Pp 78-83 (2020)

مصطلحات موضوعية: cognitive impairment, moderate cognitive impairment, non-dementia cognitive impairment, diagnosis, prevention and treatment of cognitive impairment, piribedil, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://nnp.ima-press.net/nnp/article/view/1451Test; https://doaj.org/toc/2074-2711Test; https://doaj.org/toc/2310-1342Test

الوصول الحر: https://doaj.org/article/31e0fd1cd5cd4f8fb3a6487d8eb7512fTest

المؤلفون: Alshishani, Anas, Hasan, Inas, Ghanayem, Fatima, Al-khasawneh, Sewar, Abu Dayah, Alaa

المصدر: Pharmacia 69((3)) 615-620

مصطلحات موضوعية: LC–MS/MS Method Validation Piribedil Human plasma Bioanalytical Pharmacokinetic study Bioequivalence

العلاقة: https://zenodo.org/record/6804916Test; https://doi.org/10.3897/pharmacia.63.e86447Test; oai:zenodo.org:6804916

الإتاحة: https://doi.org/10.3897/pharmacia.63.e86447Test
https://doi.org/10.3897/pharmacia.63.e86447.figure2Test
https://doi.org/10.3897/pharmacia.63.e86447.figure1Test
https://zenodo.org/record/6804916Test

المؤلفون: E. V. Moroz, T. A. Zakharycheva, M. V. Antonyuk

المصدر: Неврология, нейропсихиатрия, психосоматика, Vol 11, Iss 4, Pp 100-103 (2019)

مصطلحات موضوعية: stage iii chronic cerebrovascular insufficiency, vascular cognitive impairment, piribedil, cognitive functions, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://nnp.ima-press.net/nnp/article/view/1217Test; https://doaj.org/toc/2074-2711Test; https://doaj.org/toc/2310-1342Test

الوصول الحر: https://doaj.org/article/592826902b1f4546b11880b3547217ebTest

المؤلفون: M. E. K. Wahba, D. El Wasseef, D. El Sherbiny

المصدر: Royal Society Open Science, Vol 8, Iss 5 (2021)

مصطلحات موضوعية: hybrid micelle liquid chromatography, log P values, lipophilicity, aripiprazole, pramipexole, piribedil, Science

وصف الملف: electronic resource

العلاقة: https://doaj.org/toc/2054-5703Test

الوصول الحر: https://doaj.org/article/15a990d1a57d41f78e2920f906fe3b2eTest

المؤلفون: O. V. Vorobyeva, Zh. M. Sizova, L. M. Bogatyreva

المصدر: Неврология, нейропсихиатрия, психосоматика, Vol 11, Iss 2, Pp 52-59 (2019)

مصطلحات موضوعية: hypertension, cerebral microangiopathy, moderate cognitive impairment, piribedil, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: https://nnp.ima-press.net/nnp/article/view/1100Test; https://doaj.org/toc/2074-2711Test; https://doaj.org/toc/2310-1342Test

الوصول الحر: https://doaj.org/article/14dab0ba61034c15b2c36b61ff9af750Test

المؤلفون: Piao Zhang, Yan Li, Kun Nie, Lijuan Wang, Yuhu Zhang

المصدر: BMC Neurology, Vol 18, Iss 1, Pp 1-5 (2018)

مصطلحات موضوعية: Piribedil, Hypotension, Bradycardia, Parkinson’s disease, Adverse drug reactions, Neurology. Diseases of the nervous system, RC346-429

وصف الملف: electronic resource

العلاقة: http://link.springer.com/article/10.1186/s12883-018-1230-1Test; https://doaj.org/toc/1471-2377Test

الوصول الحر: https://doaj.org/article/11dc1d5e4edd4fa7b6b9c8a9339715f1Test